Member Info for ratcliffewriter

I share your basic scepticism about codes, and for sure the mythical '1' code is often something of a comedy feature, but your analysis from today and a good number of other occasions is at the very least substantial food for thought. In any event you always make it plain that your observations are just that, but more often than not you end up vilified from a certain quarter for posting an observation when it is put out there simply for discussion. It will be interesting to see how tomorrow unfolds anyway.

5.00-5.50. Finally!

I'll buy that one C7. The reply to your question would be interesting (or sad) but I suspect after five requests and no response you're better not holding your breath!

C7 - it's cold water, not hot water. I'll get my coat...

If ‘The Company and the Investor are currently in advanced discussions to agree the termination of the Subscription Agreement’ but 'The Company no longer intends to enter into any other arrangements with the Investor’ and ‘the Investor no longer has a holding in the Company’, does this mean they are simply negotiating the amount they have to pay to get out of the agreement – because there doesn’t seem to be anything else to talk about imo.
Then – ‘the Company's working capital position is dependent on new funds being raised in the short term.’ Does this mean ‘teetering on the brink of bankruptcy?
Then – ‘The directors are carefully managing the Company's working capital position.’ Do they want a medal for this? Or isn’t it something any company director should be doing all the time as a matter of routine?
Then – ‘The Company announces that it has arranged to dispose of its investment in an unlisted security for c.£140,000, the proceeds of which are expected to be received in the next week.’
Isn’t that about a month’s basic costs (salaries, expenses, rent of the office etc) and not much more? Or will it end up being used just to pay off the penalty clause in the ripped up financing agreement? Flogging the lawn mower on ebay is the domestic equivalent isn’t it?
Then – ‘the Company is due to receive a c. £400,000 payment from HMRC in July 2019 in relation to an R&D tax credit.’ So if it is ‘circa’ 400 grand then presumably the exact amount hasn’t been notified, and when in July? If they need to raise new funds in the short term and can only achieve that by selling an investment (so using capital to fund daily expenses) will they even get to July?
Then – ‘The directors will continue to monitor the Company's working capital position.’ I bet they will!
I’m very pleased I avoided this one in the end – but it might be worth buying a tenner’s worth just to go to the AGM and see what colour shell suit George is wearing on the day. Very tempting. Especially when you think that ten quid buys 4,000 shares, which pre-consolidation at 125 to 1 would have been 500,000 shares, and at (say) 20p that would have cost 100,000 quid. Bargain...

Let's not get distracted from here by a clash of egos shall we?

I agree with all that Cars - just be careful not to wake the children...

Good point C7 - I was trying to remember what might have prompted RG to get the original feature in the FT. It may well have been in the run up to the deal that didn't happen - I imagine they would be very careful not to repeat that scenario!

I know you are well aware of the pitfalls of BB advice DA - just needs to be in black and white for clarity. Anyway if I can make you hesitate it means there may be some cheap shares left for me if you don't buy them all...!

Never buy or sell on the advice or apparent advice of anyone on a board! Always DYOR as I am sure you know. As regards the press release, yes I do think it would take some positive effort by Scancell to get this in the FT. I don't think it is just coincidence.

I remember those comments by RG as well - it frustrated many, but in the cold light of day the job is to advance the company and make progress that stands scrutiny, not to generate headlines with no substance behind them. Given that every company at ASCO (more or less) will have prepared a press release about their attendance, and Scancell don't seem to make a fuss pushing to the front of the queue to give their press release out, I share the suspicion of several here that this press exposure could well herald something more significant being imminent.

Colour supplement by the autumn. Maybe..

Saturday's edition. Page 18. Bottom quarter of page, under 'Small Cap Focus - Pharmaceuticals.

It is the same wording as the online version that was posted here a few days ago -
When top cancer doctors gathered for the annual meeting of the American Society of Clinical Oncology last weekend, faster detection of the illness was on medics’ minds.

AstraZeneca, the Anglo-Swedish drugmaker, for example, showcased treatments intended to be administered at a much earlier stage, when the disease could still be cured.

However, successful treatment at that stage depends on speedy diagnosis.

A trio of biotech companies are seeking to play their part in faster detection and more effective treatment of this most dreaded disease, scenting the chance both to improve patients’ lives and carve out a path to profitability.

Scancell Holdings

Aim-listed Scancell, which has a market capitalisation of about £20m, has developed two technologies that harness the immune system to fight tumours.

The first, called ImmunoBody, has enabled it to produce a potential vaccine for the treatment of melanoma. Its second platform, Moditope, targets advanced or hard-to-treat cancers. Both have shown considerable promise in early studies.

Cliff Holloway, chief executive, said the company now needed to “translate the exceptional pre-clinical and lab data into clinical results”.

The company’s shares have fallen 64 per cent over the past year, due in part to the delayed start of a US clinical trial for SCIB1, a vaccine candidate generated from the ImmunoBody technology platform. The trial design has been approved by British regulatory authorities, however, and will begin in the UK in the next few weeks.

Absolutely anything can happen in AIM, as we all know only too well, but my guess is a blue day or longer coming up.

'Something for the weekend? Oh yes, a copy of Saturday's Financial Times please.'

Followed by 'Does sir require something for the weekend?'

Things really are moving on apace aren't they? All very exciting, and more so by the week almost.

Indeed - there it is on page 23. Wow! And on page 10 there is what I remember as the 'land grab' - 'Patent filed with broad claims in cancer and composition of matter for any use of homocitrullinated peptides.' (Though given my recent posting vagaries I have to add 'E&OE', naturally)

Page 18 - basically what the twitter piece said (assuming I read twitter correctly this time!) - Scancell first in the review under 'Small Cap Focus.' Very useful I suspect, and there for a reason? I think so.